Dr Vita among winners of Kaneka’s novel innovation award program
The announcement marks the end of Phase 1 of the award program, with contest winners receiving up to 5,000 free units of one of the company’s three key Floradapt products: Baby Colic, Cardio, and Intensive GI probiotic finished product.
“We had a fine group of companies demonstrate their enthusiasm for this innovative contest and are thrilled about our future collaboration with the selected winners,” said Mike Kolifrath, Vice President of the Kaneka Probiotics Division.
Due to legal approval processes, only Dr Vita has been names, but Kaneka confirmed that the other winners are “mid-sized US supplement companies”.
Phase 2 of the awards will launch at Expo West and will then provide a clinical trial grant in the amount of $150,000. This is open to all US and Canadian industry manufacturers, said the company.
Kolifrath continued: “Similar to the Free Product Contest Giveaway, applications for Phase 2 of the KIAP can be submitted by contacting us directly or turning in an application on the spot at Expo West 2020. We strongly believe in these new products to better serve today's consumer demands.”
The products
The company’s Floradapt range currently consists of eight probiotic formulations for specific health targets; cardiovascular health, baby colic, digestive health, gastrointestinal health, mature immune defense, gum health, urinary tract health, and vaginal health.
Baby Colic contains Pediococcus pentosaceus KABP-041 and Bifidobacterium longum KABP-042. Cardio contains Lactobacillus plantarum KABP-011, KABP-012, and KABP-013.
Intensive GI contains Pediococcus acidilactisi KABP-021, Lactobacillus plantarum KABP-022 and KABP-023.
Kolifrath added that Floradapt provides manufacturers with clinically validated probiotic blends to a ready to market formulation.
For more information, please click HERE.
